The untold story behind HistoSonics and the collisions that drive true medical breakthroughs

By Dr. Joe Amaral, Chief Medical and Scientific Officer at Venture Investors Health Fund

Innovation rarely happens in a straight line. It’s a story of collisions—between people, ideas, timing, and sometimes pure luck. If you trace the origin of any transformative technology, you’ll often find a series of unexpected encounters and stubborn believers who refused to let go of a good idea. The story of HistoSonics—and the development of histotripsy—is one of those journeys.

From an Idea in a Lab to a New Kind of Surgery

My career began in surgery and medical device innovation long before I joined Venture Investors Health Fund. Years ago, I co-developed a technology called Harmonic—an ultrasound-based tool that could cut and coagulate tissue simultaneously. At the time, it felt like a simple attempt to solve a surgical problem. It went on to redefine an entire field.

That experience shaped the lens through which I view innovation. It’s not about total addressable markets or spreadsheets. It’s about recognizing when a new approach can truly improve patient lives—when it can make surgery safer, faster, or unnecessary altogether.

So when I first encountered histotripsy—a noninvasive, sound-based therapy that destroys tissue without heat, radiation, or incisions—I knew I was looking at the future of surgery.

The Collisions That Make Innovation Possible

I came across the technology thanks to a call from an old colleague, Tom Davidson, who had been exploring new applications of ultrasound. He’d met a researcher at the University of Michigan working on a concept called histotripsy and thought I should see it. I flew out immediately.

In that meeting were a handful of people who would unknowingly set the next two decades in motion: Tom, the Michigan research team, and a venture capitalist named Jim Adox. Each of us came from different backgrounds—clinical, academic, financial—but we shared the same instinct: this matters.

That convergence sparked the formation of HistoSonics. Jim and his team at Venture Investors Health Fund recognized the potential to take this technology out of the lab and into the real world. My own organization at the time, Johnson & Johnson, had funded some of the early university work that made histotripsy possible. So the story began with two parallel threads—academia and industry—colliding at the right time.

The Collisions That Make Innovation Possible

Innovation rarely moves in the direction you first expect.

Early on, HistoSonics pursued benign prostatic hyperplasia (BPH) as the first clinical indication. The trial didn’t meet its endpoint—not because the technology failed, but because the endpoints weren’t quite right for the time.

Meanwhile, I had joined Johnson & Johnson’s surgical innovation group, where we were exploring new technologies for oncology. As data from the BPH trial came in, I met with Jim again. Over lunch, I told him plainly: “You should pivot to liver and pancreas.”

Those conversations led to the first successful preclinical liver studies—studies I helped design with a group of physicians who understood the potential impact. That body of work set the stage for Johnson & Johnson’s eventual investment in HistoSonics and for the company’s focus on solid tumors.

From there, the story continued to unfold—beginning with the arrival of CEO Mike Blue, who was recruited by Venture Investors Health Fund after serving as Vice President of Sales & Marketing at another one of the firm’s portfolio companies, NeuWave. His leadership brought discipline and vision to the growing organization. Soon after came the recruitment of Josh Stopek, a world-class product development expert who built the platform that exists today; and the growing community of clinicians who have validated and refined the technology in practice.

Innovation Is Never a Solo Act

People sometimes look at success stories and imagine a master plan. In reality, innovation is a relay—not a sprint. Every stage requires different hands. Without Tom, there would be no discovery. Without Jim, there would be no company. Without Mike and Stopek, there would be no product. And without countless clinicians willing to test and trust something new, there would be no impact on patients.

The path of innovation is paved with these collisions—each person arriving at just the right time to move the idea one step further.

Why the Human Element Matters

When I first looked into venture capital, I was skeptical. Too often it felt like an exercise in finance, not impact. But firms like Venture Investors Health Fund reminded me that the best venture capitalists share the same goal as the best clinicians: to improve lives.

That shared mission is what keeps innovation alive. It’s what allows a university lab in Michigan to become a clinical program saving lives around the world.

The lesson, after forty years in medicine, is simple: Innovation doesn’t happen in isolation. It happens through connection—between scientists and surgeons, investors and engineers, visionaries and pragmatists. It happens when curiosity meets persistence, and when people care enough to keep pushing until an idea becomes real.

That’s how innovation really happens.

Read More: The Stories Behind HistoSonics

• HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors – A new chapter for histotripsy and noninvasive surgery.
• The Courage to Go First: A Patient’s Story of Histotripsy and the Power of HistoSonics – How histotripsy changed one patient’s life.
• Sonic Scalpel: How HistoSonics’ Focused Ultrasound Is Redefining Tumor Treatment – Leading HistoSonics’ clinical trial in Barcelona.